دورية أكاديمية
Perioperative oncolytic virotherapy to counteract surgery-induced immunosuppression and improve outcomes in pancreatic ductal adenocarcinoma.
| العنوان: | Perioperative oncolytic virotherapy to counteract surgery-induced immunosuppression and improve outcomes in pancreatic ductal adenocarcinoma. |
|---|---|
| المؤلفون: | Mansouri S; Department of Immunology and Cell Biology, Université de Sherbrooke, Sherbrooke, QC, Canada.; Department of Surgery, Université de Sherbrooke, Sherbrooke, QC, Canada., Daniel L; Department of Surgery, Université de Sherbrooke, Sherbrooke, QC, Canada., Amhis N; Department of Immunology and Cell Biology, Université de Sherbrooke, Sherbrooke, QC, Canada.; Department of Surgery, Université de Sherbrooke, Sherbrooke, QC, Canada., Leveille M; Department of Immunology and Cell Biology, Université de Sherbrooke, Sherbrooke, QC, Canada., Boudreau JE; Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada., Alkayyal AA; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.; Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Collin Y; Department of Surgery, Université de Sherbrooke, Sherbrooke, QC, Canada.; Research Center of the Centre hospitalier universitaire de Sherbrooke (CHUS), Sherbrooke, QC, Canada., Tai LH; Department of Immunology and Cell Biology, Université de Sherbrooke, Sherbrooke, QC, Canada.; Research Center of the Centre hospitalier universitaire de Sherbrooke (CHUS), Sherbrooke, QC, Canada. |
| المصدر: | Frontiers in oncology [Front Oncol] 2023 Feb 16; Vol. 13, pp. 1071751. Date of Electronic Publication: 2023 Feb 16 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Pancreatic ductal adenocarcinoma (PDAC) is a high fatality cancer with one of the worst prognoses in solid tumors. Most patients present with late stage, metastatic disease and are not eligible for potentially curative surgery. Despite complete resection, the majority of surgical patients will recur within the first two years following surgery. Postoperative immunosuppression has been described in different digestive cancers. While the underlying mechanism is not fully understood, there is compelling evidence to link surgery with disease progression and cancer metastasis in the postoperative period. However, the idea of surgery-induced immunosuppression as a facilitator of recurrence and metastatic spread has not been explored in the context of pancreatic cancer. By surveying the existing literature on surgical stress in mostly digestive cancers, we propose a novel practice-changing paradigm: alleviate surgery-induced immunosuppression and improve oncological outcome in PDAC surgical patients by administering oncolytic virotherapy in the perioperative period. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Mansouri, Daniel, Amhis, Leveille, Boudreau, Alkayyal, Collin and Tai.) |
| References: | Front Oncol. 2019 Sep 10;9:855. (PMID: 31552179) Cancer Cell. 2012 Jun 12;21(6):822-35. (PMID: 22698406) Am Soc Clin Oncol Educ Book. 2017;37:267-278. (PMID: 28561678) Nat Rev Drug Discov. 2019 Sep;18(9):689-706. (PMID: 31292532) Cancers (Basel). 2021 Mar 09;13(5):. (PMID: 33803211) Ann Gastroenterol Surg. 2019 Jul 01;3(5):464-475. (PMID: 31549006) J Surg Oncol. 2021 May;123(6):1475-1488. (PMID: 33831245) J Clin Oncol. 2007 Apr 20;25(12):1562-9. (PMID: 17443000) Eur J Cancer. 2009 Jul;45(11):1950-8. (PMID: 19231158) JAMA. 2021 Sep 7;326(9):851-862. (PMID: 34547082) Oncogene. 2014 Jun 5;33(23):2956-67. (PMID: 23851493) Int J Mol Sci. 2021 Dec 14;22(24):. (PMID: 34948209) Brain Behav Immun. 2013 Mar;30 Suppl:S32-40. (PMID: 22504092) Cancers (Basel). 2022 May 14;14(10):. (PMID: 35626033) Gastroenterology. 2013 Nov;145(5):1121-32. (PMID: 23891972) J Pathol. 2019 May;248(1):51-65. (PMID: 30575030) J Surg Oncol. 2021 Mar;123(3):751-759. (PMID: 33595893) Biochim Biophys Acta. 2012 Aug;1826(1):170-8. (PMID: 22521638) Chin Med J (Engl). 2015 Jun 5;128(11):1502-9. (PMID: 26021508) Front Oncol. 2021 Dec 08;11:788918. (PMID: 34956903) Nat Cell Biol. 2000 Oct;2(10):737-44. (PMID: 11025665) Front Oncol. 2021 Oct 06;11:751311. (PMID: 34692532) Cancer Immunol Res. 2022 Jun 3;10(6):745-756. (PMID: 35439304) J Clin Oncol. 2022 Apr 10;40(11):1220-1230. (PMID: 35084987) Cancer Lett. 2021 Apr 28;504:1-14. (PMID: 33549709) Eur Surg Res. 2012;48(4):180-6. (PMID: 22653168) PLoS One. 2016 May 19;11(5):e0155947. (PMID: 27196057) Cancer Treat Rev. 2020 Jun;86:102016. (PMID: 32247999) J Surg Oncol. 2019 Dec;120(7):1102-1111. (PMID: 31598983) Clin Cancer Res. 2012 Sep 15;18(18):4895-902. (PMID: 22753587) Front Oncol. 2022 Sep 05;12:935231. (PMID: 36132127) J Exp Clin Cancer Res. 2019 Apr 15;38(1):162. (PMID: 30987642) J Surg Res. 2012 Apr;173(2):299-308. (PMID: 21195425) Cancer Res. 2013 Jan 1;73(1):97-107. (PMID: 23090117) Clin Exp Metastasis. 2018 Apr;35(4):319-331. (PMID: 29728948) CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204) Front Oncol. 2020 Feb 28;10:245. (PMID: 32185128) J Immunother Cancer. 2020 Mar;8(1):. (PMID: 32179632) JAMA Netw Open. 2021 Apr 1;4(4):e214708. (PMID: 33825840) Cancers (Basel). 2022 Feb 16;14(4):. (PMID: 35205732) EBioMedicine. 2018 May;31:17-24. (PMID: 29724655) HPB (Oxford). 2020 Sep;22(9):1240-1249. (PMID: 32046922) Cancers (Basel). 2018 Jan 03;10(1):. (PMID: 29301364) Gastroenterology. 2018 Sep;155(3):880-891.e8. (PMID: 29909021) J Cell Mol Med. 2019 Jun;23(6):3878-3887. (PMID: 30941918) Cancer Cell Int. 2021 Apr 7;21(1):196. (PMID: 33827590) Trends Cancer. 2020 Nov;6(11):951-959. (PMID: 32654993) JCI Insight. 2018 Apr 5;3(7):. (PMID: 29618658) Mol Cancer. 2019 Sep 2;18(1):132. (PMID: 31477121) Cancers (Basel). 2021 Feb 27;13(5):. (PMID: 33673405) Cancers (Basel). 2022 Jul 05;14(13):. (PMID: 35805064) J Immunother Cancer. 2022 Apr;10(4):. (PMID: 35414592) Clin Cancer Res. 2021 Oct 15;27(20):5546-5556. (PMID: 34426438) World J Surg. 2011 Apr;35(4):868-72. (PMID: 21312035) J Hepatobiliary Pancreat Sci. 2021 May;28(5):419-430. (PMID: 33742512) Cancer Res. 2014 Jun 1;74(11):2913-21. (PMID: 24840647) Nat Rev Clin Oncol. 2020 May;17(5):313-326. (PMID: 32066936) Arch Surg. 2005 Jul;140(7):692-7. (PMID: 16027336) Pancreas. 2015 Apr;44(3):386-93. (PMID: 25621568) Front Oncol. 2019 Dec 06;9:1370. (PMID: 31921634) J Clin Oncol. 2011 Jul 20;29(21):2845-51. (PMID: 21670457) Ann Surg Oncol. 2003 Oct;10(8):972-92. (PMID: 14527919) Curr Opin Oncol. 2017 Sep;29(5):359-365. (PMID: 28678032) BMC Cancer. 2020 Aug 11;20(1):750. (PMID: 32782024) Cancer Immunol Immunother. 2014 Jan;63(1):59-65. (PMID: 24129765) Ann Surg. 2013 Jul;258(1):158-68. (PMID: 23108132) J Surg Oncol. 2004 Dec 15;88(4):240-7. (PMID: 15565596) Clin Transl Med. 2020 Jan;10(1):199-223. (PMID: 32508035) Exp Cell Res. 2018 Sep 15;370(2):692-698. (PMID: 30055136) Biomedicines. 2022 Feb 12;10(2):. (PMID: 35203640) World J Gastroenterol. 2014 Mar 7;20(9):2237-46. (PMID: 24605023) J Clin Oncol. 2009 Oct 1;27(28):4709-17. (PMID: 19720929) Cancers (Basel). 2010 Nov 24;2(4):1929-51. (PMID: 24281210) J Invest Surg. 2005 Mar-Apr;18(2):81-8. (PMID: 16036776) Mol Ther. 2016 Jun;24(6):1150-1158. (PMID: 27039845) J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79. (PMID: 11307091) J Immunother Cancer. 2016 Mar 15;4:14. (PMID: 26981244) Nat Rev Drug Discov. 2019 Mar;18(3):197-218. (PMID: 30610226) Sci Signal. 2020 Sep 08;13(648):. (PMID: 32900881) J Clin Oncol. 2022 Aug 20;40(24):2789-2805. (PMID: 35839445) Oncoimmunology. 2018 Mar 1;7(6):e1431082. (PMID: 29872554) Br J Cancer. 2006 Nov 6;95(9):1167-73. (PMID: 17031403) Nature. 2020 May;581(7806):100-105. (PMID: 32376951) Ann Thorac Surg. 2008 Dec;86(6):1735-44. (PMID: 19021967) Int J Clin Exp Med. 2015 May 15;8(5):7816-22. (PMID: 26221334) J Clin Oncol. 2016 Jul 20;34(21):2541-56. (PMID: 27247221) J Transl Med. 2018 Jan 18;16(1):8. (PMID: 29347949) Lancet Gastroenterol Hepatol. 2016 Dec;1(4):298-306. (PMID: 28404200) J Gastrointest Surg. 2017 Oct;21(10):1723-1731. (PMID: 28744743) Tumour Biol. 2017 May;39(5):1010428317698368. (PMID: 28459196) Clin Cancer Res. 2012 Aug 15;18(16):4266-76. (PMID: 22896693) Eur J Clin Invest. 2000 Mar;30(3):230-8. (PMID: 10692000) J Immunother Cancer. 2022 May;10(5):. (PMID: 35640930) Front Surg. 2022 Jul 11;9:888630. (PMID: 35898583) PLoS One. 2018 Sep 13;13(9):e0203795. (PMID: 30212506) Am J Cancer Res. 2020 Jul 01;10(7):1937-1953. (PMID: 32774994) J Clin Invest. 2013 Jul 1;:. (PMID: 23863628) J Immunother Cancer. 2018 Sep 3;6(1):86. (PMID: 30176921) Front Cell Dev Biol. 2021 Dec 10;9:787249. (PMID: 34957115) Ann Surg. 2000 Dec;232(6):786-95. (PMID: 11088073) Front Immunol. 2021 May 18;12:674400. (PMID: 34084172) Clin Cancer Res. 2020 Jan 1;26(1):71-81. (PMID: 31694832) Cancer Cell. 2021 Oct 11;39(10):1342-1360.e14. (PMID: 34358448) Ann Surg. 2011 Apr;253(4):798-810. (PMID: 21475023) N Engl J Med. 2018 Dec 20;379(25):2395-2406. (PMID: 30575490) BMC Cancer. 2016 Oct 26;16(1):823. (PMID: 27782813) Int J Mol Sci. 2020 Jul 31;21(15):. (PMID: 32752017) J Exp Clin Cancer Res. 2004 Jun;23(2):195-200. (PMID: 15354402) JSLS. 2021 Jan-Mar;25(1):. (PMID: 33879996) Ann Surg Oncol. 2022 Aug;29(8):4992-5002. (PMID: 35368218) Arq Bras Cir Dig. 2014 Nov-Dec;27(4):275-9. (PMID: 25626938) Nat Rev Immunol. 2018 Aug;18(8):498-513. (PMID: 29743717) Anticancer Res. 2008 May-Jun;28(3B):1951-4. (PMID: 18630487) Front Physiol. 2015 May 15;6:125. (PMID: 26029109) Cancer Res. 2017 Apr 1;77(7):1548-1552. (PMID: 28330928) Viruses. 2019 May 11;11(5):. (PMID: 31083491) Transl Oncol. 2020 Dec;13(12):100856. (PMID: 32862105) J Formos Med Assoc. 2020 Nov;119(11):1673-1683. (PMID: 32081564) Surgeon. 2011 Feb;9(1):38-43. (PMID: 21195330) Nat Rev Clin Oncol. 2016 Oct;13(10):593-4. (PMID: 27531701) Cancer Metastasis Rev. 2021 Sep;40(3):675-689. (PMID: 34591240) J Urol. 2001 Sep;166(3):831-6. (PMID: 11490228) Oncoimmunology. 2013 Nov 1;2(11):e26618. (PMID: 24404430) Cancer Treat Rev. 2014 May;40(4):513-22. (PMID: 24315741) BMC Cancer. 2018 May 25;18(1):596. (PMID: 29801474) Cancer. 2012 Mar 15;118(6):1726-37. (PMID: 21953630) Clin Cancer Res. 2015 Mar 15;21(6):1406-18. (PMID: 25391696) JAMA Netw Open. 2020 Apr 1;3(4):e203850. (PMID: 32347950) Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):E415-24. (PMID: 23271806) |
| فهرسة مساهمة: | Keywords: immunosuppression; neoadjuvant; oncolytic virus; pancreatic cancer; pancreatic ductal adenocarcinoma (PADC); perioperative period; surgery; tumor microenvironment |
| تواريخ الأحداث: | Date Created: 20230306 Latest Revision: 20230307 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9978493 |
| DOI: | 10.3389/fonc.2023.1071751 |
| PMID: | 36874130 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2023.1071751 |